Destiny Pharma plc Shares Now Trading on JP Jenkins

London, UK, 13th Aug 2024 - Destiny Pharma plc, a clinical-stage biotechnology company, announces that its shares are now trading on the JP Jenkins share dealing platform. This move aims to facilitate the buying and selling of Destiny Pharma’s equity by shareholders and potential investors through a matched bargain basis.

Destiny Pharma focuses on developing and commercializing innovative medicines that prevent and cure life-threatening infections. Among its leading assets are the XF-73 Nasal gel, targeting post-surgical staphylococcal hospital infections, including MRSA, and NTCD-M3, a biotherapeutic aimed at preventing the recurrence of C. difficile infection (CDI).

JP Jenkins provides a trading venue for unlisted or unquoted assets, enabling trades during regular business hours. The indicative pricing and transaction history of Destiny Pharma's ordinary shares (ISIN: GB00BDHSP575) will be available on the JP Jenkins website.

Commercial Director of JP Jenkins, Veronika Oswald, welcomed Destiny Pharma to their platform, expressing delight in supporting the company’s transition and growth.